GH Research Q1 2025 Earnings Report

GH Research EPS Results

• Actual EPS: -$0.19
• Consensus EPS: -$0.61
• Beat/Miss: Beat by +$0.42
• One Year Ago EPS: N/A

GH Research Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

GH Research Announcement Details

• Quarter: Q1 2025
• Date: 5/8/2025
• Time: Before Market Opens
• Conference Call Date: Wednesday, May 7, 2025
• Conference Call Time: 6:00PM ET

GH Research (NASDAQ:GHRS) (NASDAQ:GHRS) is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for psychiatric disorders. Founded to address significant unmet needs in mental health, the company’s research program focuses on fast-acting treatments that could provide rapid relief for patients suffering from major depressive disorder, post-traumatic stress disorder and other mood-related conditions. GH Research leverages proprietary chemistry and advanced delivery technologies to create a pipeline of next-generation compounds designed to work through unique mechanisms of action.

The company’s lead candidate, GH001, is an inhaled formulation of a differentiated phencyclidine analogue being evaluated for treatment-resistant depression. GH001 is engineered for rapid onset of action and precise dosing, with the goal of reducing the time to therapeutic effect compared to existing therapies. Earlier-stage assets in GH Research’s portfolio include novel ketamine- and MDMA-inspired compounds currently in preclinical development, each targeting distinct neurochemical pathways implicated in mood regulation and stress response.

GH Research maintains its headquarters in Dublin, Ireland, with additional research and development operations in the United Kingdom and the United States. The company collaborates with academic institutions and contract research organizations to conduct its clinical trials and to advance its understanding of psychedelic-inspired medicines. Through these partnerships, GH Research aims to generate robust clinical data that could support expedited pathways to regulatory approval.

Leadership at GH Research is composed of seasoned executives and board members with deep experience in neuroscience, drug development and regulatory affairs. The management team draws on expertise from both large pharmaceutical companies and nimble biotech startups to navigate the complexities of psychiatric drug development. With a commitment to scientific rigor and patient safety, GH Research is positioned to push the boundaries of current treatment paradigms and bring transformative therapies to individuals living with serious mental health disorders.